{
    "root": "2ebf334e-6f66-4ef7-b0ca-9d21ccb3165e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Lurasidone Hydrochloride"
    },
    "value": "20250224",
    "ingredients": [
        {
            "name": "LURASIDONE HYDROCHLORIDE",
            "code": "O0P4I5851I"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "ALGINIC ACID",
            "code": "8C3Z4148WZ"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "Lurasidone hydrochloride tablet is indicated for:\n                  \n                     Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies (14.1)].\n                     \n                     Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].\n                     \n                     Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].",
    "contraindications": "Lurasidone hydrochloride tablets should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone hydrochloride tablets (2.3, 12.3). Indication Starting Dose Recommended Dose Schizophrenia – adults (2.1) 40 mg per day 40 mg to 160 mg per day Schizophrenia – adolescents (13 to 17 years) (2.1) 40 mg per day 40 mg to 80 mg per day Bipolar Depression – adults (2.2) 20 mg per day 20 mg to 120 mg per day Bipolar Depression – pediatric patients (10 to 17 years) (2.2) 20 mg per day 20 mg to 80 mg per day Moderate and Severe Renal Impairment: Recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day (2.4, 8.6). Moderate and Severe Hepatic Impairment: Recommended starting dose is 20 mg per day. The maximum recommended dose is 80 mg per day in moderate hepatic impairment and 40 mg per day in severe hepatic impairment (2.5, 8.7). Concomitant Use of a Moderate CYP3A4 inhibitor (e.g., diltiazem): Lurasidone hydrochloride tablets dose should be reduced to half of the original dose level. Recommended starting dose is 20 mg per day. Maximum recommended dose is 80 mg per day (2.6, 7.1). Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of lurasidone hydrochloride tablets (2.6, 7.1).",
    "warningsAndPrecautions": "Lurasidone hydrochloride tablets are available as follows:  \n                  \n                     20 mg: White to off-white, round, film-coated tablet, debossed with '578' on one side and plain on other side.\n                  Bottles of 30 with Child Resistant Cap…………………..NDC 47335-578-83\n                  Bottles of 90 with Child Resistant Cap………………..…NDC 47335-578-81\n                  Bottles of 500……………………………………….……NDC 47335-578-13\n                  \n                  \n                     40 mg: White to off-white, round, film-coated tablet, debossed with '684' on one side and plain on other side.\n                  Bottles of 30 with Child Resistant Cap…………………..NDC 47335-684-83\n                  Bottles of 90 with Child Resistant Cap………………..…NDC 47335-684-81\n                  Bottles of 500……………………………………….……NDC 47335-684-13\n                  \n                  \n                     60 mg: White to off-white, modified capsule shaped, film-coated tablet, debossed with '639' on one side and plain on other side.\n                  Bottles of 30 with Child Resistant Cap…………………..NDC 47335-639-83\n                  Bottles of 90 with Child Resistant Cap………………..…NDC 47335-639-81\n                  Bottles of 500……………………………………….……NDC 47335-639-13\n                  \n                  \n                     80 mg: Pale green colored, oval shaped, film-coated tablet, debossed with '685' on one side and plain on other side.\n                  Bottles of 30 with Child Resistant Cap…………………..NDC 47335-685-83\n                  Bottles of 90 with Child Resistant Cap………………..…NDC 47335-685-81\n                  Bottles of 500……………………………………….……NDC 47335-685-13\n                  \n                  \n                     120 mg: White to off-white, oval shaped, film-coated tablet, debossed with '579' on one side and plain on other side.\n                  Bottles of 30 with Child Resistant Cap…………………..NDC 47335-579-83\n                  Bottles of 90 with Child Resistant Cap………………..…NDC 47335-579-81\n                  Bottles of 500……………………………………….……NDC 47335-579-13\n                         \n                     \n                  \n                  \n                      \n                  \n                  \n                     \n                        Storage\n                     \n                  \n                  Store lurasidone hydrochloride tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].",
    "adverseReactions": "Known  hypersensitivity  to  lurasidone  hydrochloride or  any  components  in  the  formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.1)].\n                     Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions (7.1)].\n                     \n                     Strong CYP3A4  inducers  (e.g.,  rifampin,  avasimibe,  St.  John’s wort, phenytoin, carbamazepine, etc.) [see Drug Interactions (7.1)]."
}